Skip to main content
Top
Published in: Digestive Diseases and Sciences 3/2016

01-03-2016 | Original Article

Glucagon Is a Safe and Inexpensive Initial Strategy in Esophageal Food Bolus Impaction

Authors: Jason Haas, Julia Leo, Nimish Vakil

Published in: Digestive Diseases and Sciences | Issue 3/2016

Login to get access

Abstract

Background

Controversy exists about the utility of pharmacologic agents and endoscopic technique used for esophageal food bolus impaction.

Aim

To evaluate the utility of glucagon and the technique used for endoscopic removal, including the rate of success and the adverse events of the techniques.

Methods

The database of the largest healthcare provider in southeastern Wisconsin was retrospectively reviewed for patients presenting with esophageal food bolus impaction. Data extracted included glucagon administration and its success rate, outcome of radiographic studies, and the endoscopic method of removal and adverse events associated with it, including 30-day mortality.

Results

A total of 750 patients were identified with food bolus impaction from 2007 to 2012. Glucagon was administered in 440 patients and was successful in 174 (39.5 %). Endoscopic removal was performed in 470 patients and was successful in 469 (99.8 %). The push technique was utilized in 209 patients, reduction in the bolus size by piecemeal removal followed by the push technique was utilized in 97 patients, and the pull technique was utilized in 107 patients. There were no perforations with endoscopic removal. Only 4.5 % of the X-rays performed reported a possible foreign body within the esophagus. Glucagon was a significantly less-expensive strategy than endoscopic therapy (p < 0.0001).

Conclusion

Glucagon is low cost, is moderately effective, and may be considered as an initial strategy. Endoscopic removal regardless of technique is safe and effective. The yield of radiography is poor in the setting of food bolus impaction.
Literature
1.
go back to reference Colon V, Grade A, Pulliam G, et al. Effect of doses of glucagon used to treat food impaction on esophageal motor function of normal subjects. Dysphagia. 1999;14:27–30.CrossRefPubMed Colon V, Grade A, Pulliam G, et al. Effect of doses of glucagon used to treat food impaction on esophageal motor function of normal subjects. Dysphagia. 1999;14:27–30.CrossRefPubMed
2.
go back to reference Tibbling L, Bjorkhole A, Jansson E, et al. Effect of spasmolytic drugs on esophageal foreign bodies. Dysphagia. 1995;10:126–127.CrossRefPubMed Tibbling L, Bjorkhole A, Jansson E, et al. Effect of spasmolytic drugs on esophageal foreign bodies. Dysphagia. 1995;10:126–127.CrossRefPubMed
3.
go back to reference Sodeman TC, Harewood GC, Baron TH. Assessment of the predictors of response to glucagon in the setting of acute esophageal food bolus impaction. Dysphagia. 2004;19:18–21.CrossRefPubMed Sodeman TC, Harewood GC, Baron TH. Assessment of the predictors of response to glucagon in the setting of acute esophageal food bolus impaction. Dysphagia. 2004;19:18–21.CrossRefPubMed
4.
go back to reference Arora S, Galich P. Myth: glucagon is an effective first-line therapy for esophageal foreign body impaction. CJEM. 2009;11:169–171.PubMed Arora S, Galich P. Myth: glucagon is an effective first-line therapy for esophageal foreign body impaction. CJEM. 2009;11:169–171.PubMed
5.
go back to reference Thimmapuram J, Oosterveen S, Grim R. Use of glucagon in relieving esophageal food bolus impaction in the era of eosinophilic esophageal infiltration. Dysphagia. 2013;28:212–216.CrossRefPubMed Thimmapuram J, Oosterveen S, Grim R. Use of glucagon in relieving esophageal food bolus impaction in the era of eosinophilic esophageal infiltration. Dysphagia. 2013;28:212–216.CrossRefPubMed
6.
go back to reference Robbins MI, Shortsleeve MJ. Treatment of acute esophageal food impaction with glucagon, an effervescent agent, and water. Am J Roentgenol. 1994;162:325–328.CrossRef Robbins MI, Shortsleeve MJ. Treatment of acute esophageal food impaction with glucagon, an effervescent agent, and water. Am J Roentgenol. 1994;162:325–328.CrossRef
7.
go back to reference American Society for Gastrointestinal Endoscopy. Guidelines: Management of ingested foreign bodies and food impactions. Gastrointest Endosc. 2011;73:1085–1091.CrossRef American Society for Gastrointestinal Endoscopy. Guidelines: Management of ingested foreign bodies and food impactions. Gastrointest Endosc. 2011;73:1085–1091.CrossRef
8.
go back to reference Desai TK, Stecevic V, Chang CH, Goldstein NS, Badizadegan K, Furuta GT. Association of eosinophilic inflammation with esophageal food impaction in adults. Gastrointest Endosc. 2005;61:795–801.CrossRefPubMed Desai TK, Stecevic V, Chang CH, Goldstein NS, Badizadegan K, Furuta GT. Association of eosinophilic inflammation with esophageal food impaction in adults. Gastrointest Endosc. 2005;61:795–801.CrossRefPubMed
9.
go back to reference Sugawa C, Ono H, Taleb M, Lucas CE. Endoscopic management of foreign bodies in the upper gastrointestinal tract: A review. World J Gastrointest Endosc. 2014;6:475–481.PubMedCentralCrossRefPubMed Sugawa C, Ono H, Taleb M, Lucas CE. Endoscopic management of foreign bodies in the upper gastrointestinal tract: A review. World J Gastrointest Endosc. 2014;6:475–481.PubMedCentralCrossRefPubMed
Metadata
Title
Glucagon Is a Safe and Inexpensive Initial Strategy in Esophageal Food Bolus Impaction
Authors
Jason Haas
Julia Leo
Nimish Vakil
Publication date
01-03-2016
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 3/2016
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-015-3934-z

Other articles of this Issue 3/2016

Digestive Diseases and Sciences 3/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.